
BAX AI Price Prediction
Track BAX's AI-powered predictions, market trends, and investment insights.
You don't hold BAX in your mock portfolio yet.
Track BAX's AI-powered predictions, market trends, and investment insights.
You don't hold BAX in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedThe negative EPS of -1.91 and a corresponding negative PE ratio of -10.73 indicate that Baxter International is currently unprofitable on a GAAP basis. This points to earnings pressure, likely from restructuring, write‑downs, or operating challenges, which weighs on the fundamental investment case despite any short‑term stock price strength. Until visibility improves on a return to sustained positive earnings, the financial profile skews negative.
The stock has risen 15.2% over the last month and is trading modestly above its 200‑day moving average at $20.49 versus $19.79, indicating improving momentum and a tentative shift toward a more constructive trend. However, the premium to the 200‑day average is relatively small, suggesting the move is still early and could be vulnerable to reversal, especially given the lack of profitability. Without additional data such as RSI, the technical picture is cautiously constructive but not decisively bullish.
Alternative data for Baxter International show a mixed but slightly constructive picture. Job openings are relatively high at 740 and growing 6.2% month over month, which can indicate planned expansion or investment in capabilities. Web traffic is sizable at roughly 485k monthly visitors, while social media followership is broadly stable with modest growth on LinkedIn and YouTube offset by small declines on Twitter/X and Instagram, suggesting steady but not rapidly accelerating engagement.
Overall, Baxter International’s setup appears neutral: the stock shows improving short‑term momentum and modest technical strength, but this is offset by negative earnings and an unresolved profitability profile. Alternative data such as hiring growth and stable professional engagement on LinkedIn hint at ongoing operational activity and potential for improvement, yet they do not fully counterbalance the current lack of profitability. The stock’s near‑term trajectory will likely depend on evidence that operational initiatives can translate into sustained positive earnings.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Baxter International (BAX) is trading at $18.4 on the NYSE, declining 2.0% in the latest session on volume of over 6.8 million shares — a level that suggests active selling rather than routine drift. With a market capitalization of $9.5 billion, BAX operates across a broad healthcare product portfolio spanning dialysis therapies, infusion systems, surgical hemostasis, parenteral nutrition, and pharmacy compounding services. The stock's current price reflects a company navigating significant operational and financial headwinds, and today's session move reinforces that near-term momentum remains firmly negative.
TrendEdge's AI model assigns BAX a score of 4 out of 10, placing it in bearish territory. This score aggregates signals across price momentum, volume dynamics, and sentiment indicators. The 2.0% single-day decline on elevated volume of 6.8 million shares contributes to a weak momentum reading, while social sentiment data for the past seven days shows just one Reddit mention with no measurable positive or negative signal — indicating minimal retail investor conviction in either direction. A score of 4/10 does not suggest imminent collapse, but it does indicate the weight of evidence currently favors caution over accumulation.
Looking ahead, the key catalysts for BAX center on its ongoing portfolio restructuring — particularly the separation of its kidney care business — and its ability to reduce a substantial debt load. Execution risk remains elevated given the complexity of these moves. Investors should watch for earnings guidance updates, debt refinancing progress, and any margin improvement in its hospital products segments. Until the AI score shows meaningful recovery above 6/10 and price momentum stabilizes, the risk-reward profile warrants a defensive stance.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
485,562
Twitter Followers
16,248
Instagram Followers
326
YouTube Subscribers
3,730
LinkedIn Followers
1,277,110
Job Postings
754
LinkedIn Employees
39,170
News Mentions
0
Key Metrics